XZP-7797 / Sihuan Pharmaceutical - LARVOL DELTA

A Phase 1, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of XZP-7797-H1 in Chinese Patients with Advanced/Metastatic Solid Tumors (ChiCTR) - P1 | N=56 | Not yet recruiting | Sponsor: Beijing Cancer Hospital; Xuanzhu Biopharmaceutical Co., Ltd./Shandong XuanZhu Pharma Co., Ltd.

New P1 trial • Ovarian Cancer • Solid Tumor • BRCA1 • BRCA2 • HRD

Discovery of a potent, selective and brain penetrating PARP1 inhibitor, XZP-7797 (AACR 2024) - "Additionally, XZP-7797 has great PK profiles in preclinical species after oral dosing and good ADME properties. In a 14-day toxicology study of XZP-7797 in SD Rats, XZP-7797 has no hematological adverse effects at the exposure that is 10 times higher than the exposure required to achieve superior efficacy."

Late-breaking abstract • Breast Cancer • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor • BRCA • BRCA1 • BRCA2 • HRD • PARP2 • PARP3 • TNKS2